Glenmark Pharmaceuticals has a total of 2655 patents globally, out of which 909 have been granted. Of these 2655 patents, 22.29 % patents are active. India is where Glenmark Pharmaceuticals has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, India seems to be the main focused R&D centre and also is the origin country of Glenmark Pharmaceuticals.
Founded in 1977, Glenmark Pharmaceuticals is a global pharmaceutical company focused on developing, manufacturing, and commercializing innovative medicines and generic formulations. The company’s portfolio spans key therapeutic areas, including dermatology, respiratory diseases, and oncology, with a focus on specialty medicines, branded generics, and complex generics. Glenmark continues to strengthen its research and development capabilities and expand its presence across international markets, aiming to address unmet medical needs through differentiated therapies, product innovation, and accessible treatment options.
Glenmark’s Oncology Innovation Secures $700 Million Upfront in AbbVie Licensing Deal
In July 2025, Glenmark’s wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), signed a licensing agreement with AbbVie for ISB 2001. The deal generated $700 million in upfront licensing revenue, received in September 2025, with an additional $1.225 billion in potential milestone payments. This represents a significant commercial achievement for Glenmark’s oncology research, although the upfront payment should not be interpreted as net profit.
Do read about some of the most notable patents of Glenmark Pharmaceuticals covered in this article. You can also explore Glenmark Pharmaceuticals’ patent portfolio, worldwide patent filing activity, patent filing trends over the years, and many other statistics related to its patent portfolio.
How many patents does Glenmark Pharmaceuticals have?
Glenmark Pharmaceuticals has a total of 2655 patents globally. These patents belong to 717 unique patent families. Out of 2655 patents, 592 patents are active.
How Many Patents did Glenmark Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Glenmark Pharmaceuticals Applications Filed | Glenmark Pharmaceuticals Patents Granted |
| 2026 | 3 | 6 |
| 2025 | 16 | 18 |
| 2024 | 25 | 10 |
| 2023 | 53 | 20 |
| 2022 | 21 | 40 |
| 2021 | 51 | 47 |
| 2020 | 50 | 76 |
| 2019 | 148 | 70 |
| 2018 | 165 | 77 |
| 2017 | 68 | 40 |
| 2016 | 121 | 63 |
Glenmark Pharmaceuticals 2019 R&D Restructuring and Its Impact on Patent Filings
In 2019, Glenmark separated its innovative R&D business into a new U.S.-based company, Ichnos Sciences, focusing on oncology, immunology, and pain management. This restructuring marked a shift in how Glenmark managed its research activities and patent portfolio.
The separation may have contributed to the decline in patent filings after 2019 as research priorities and patent ownership changed. However, the patent dataset shows that filings declined for both Glenmark and Ichnos, suggesting a broader reduction in patenting activity rather than simply a transfer of patents to the new entity.
Changes in Glenmark Pharmaceuticals patent-family technology mix
| Technology area | 2015-2019 families | 2020-2024 families | Change in portfolio focus |
| Oncology, biologics and immune-related R&D | 23 (14.6%) | 17 (50.0%) | Strong increase in share |
| Respiratory formulations and inhaler devices | 32 (20.3%) | 6 (17.6%) | Remains relevant, but fewer new families |
| Diabetes-related formulations | 11 (7.0%) | 5 (14.7%) | Higher share within a much smaller portfolio |
| Other pharmaceutical formulations and processes | 92 (58.2%) | 6 (17.6%) | Substantial reduction |
| Total | 158 | 34 | Smaller, more concentrated portfolio |
The most significant observation is that oncology-related technologies represented 50% of recorded new patent families in 2020-2024, compared with approximately 15% in 2015-2019.
This does not mean oncology filings increased in absolute terms. They decreased from 23 to 17 families. Their share increased because filing activity in other pharmaceutical areas contracted more sharply.
The magnitude of contraction makes the change in mix more meaningful. Total new families fell from 158 in 2015-2019 to 34 in 2020-2024 (78.5%). Oncology, biologics and immune-related families fell from 23 to 17 (26.1%), whereas other pharmaceutical formulation and process families fell from 92 to 6 (93.5%). Oncology therefore increased from 14.6% to 50.0% of the smaller recent cohort without an increase in absolute oncology-related family counts. This suggests greater relative concentration, not expanding patenting volume in that category.
Also, 2024 and later priority-year results can be incomplete because of patent publication delays and search coverage. The table should therefore be used to identify a portfolio direction, not to claim that it captures every invention in those years.
How many Glenmark Pharmaceuticals patents are Alive/Dead?
Glenmark Pharmaceuticals Patent Portfolio: How Much Protection Has Been Lost?
Glenmark’s patent portfolio analysis reveals substantial attrition across jurisdictions and legal-status categories. Of the 2,655 analysed patent records, 1,734 (65.3%) fall into the listed inactive, withdrawn, abandoned, rejected, ceased, expired, revoked, or discontinued categories, based on the recorded status counts. This includes 422 records (15.9%) marked inactive due to non-payment of maintenance fees, 379 (14.3%) deemed withdrawn, 371 (14.0%) withdrawn for undetermined reasons, 154 (5.8%) abandoned for undetermined reasons, and another 154 (5.8%) rejected during patent-office proceedings. The dataset also includes 105 ceased records, 50 discontinued proceedings, 36 deemed-abandoned records, 33 expired records, 21 revoked records, and 9 voluntarily withdrawn records.
These figures highlight the scale of recorded portfolio attrition and the importance of understanding why patent rights or applications become inactive. However, these statuses do not all indicate the same outcome: some applications may never have resulted in granted patents, while others may have lost protection or been deliberately withdrawn. The remaining 34.7% should not automatically be considered active without further legal-status verification.
This is where proactive patent monitoring becomes critical. GreyB’s Elixir platform helps IP teams track patent legal-status changes, maintenance-fee events, prosecution developments, and other critical patent activities in real time. By monitoring these events, teams can identify important changes earlier, investigate potential deadline risks, and make more informed decisions about their patent portfolios.
Don’t Let Critical Patent Events Go Unnoticed. Monitor legal-status changes, maintenance deadlines, and prosecution events with Elixir.
Track Every Patent Move in Real Time Across 70+ Jurisdictions with Elixir
Patent Lapses and Abandonments: What Explains the Loss of Patent Protection in Glenmark Pharmaceuticals Portfolio?
| Recorded reason | Records | Unique INPADOC families | Interpretation |
| Non-payment | 422 | 105 | Maintenance/renewal fee non-payment indicated |
| Withdrawn – Deemed | 379 | 183 | Application deemed withdrawn; exact cause not supplied |
| Withdrawn – Undetermined | 371 | 282 | Withdrawn, but reason not specified |
| Abandoned – Undetermined | 154 | 90 | Application abandoned; exact cause not specified |
| Rejected | 154 | 74 | Application rejected during patent-office proceedings |
| Ceased | 105 | 55 | Patent rights ceased; specific cause not given |
| Discontinuation | 50 | 50 | Application proceedings discontinued |
| Abandoned – Deemed | 36 | 33 | Deemed abandoned; office-action non-response is possible but unconfirmed |
| Expired | 33 | 9 | Recorded as expired; precise expiry basis not specified |
| Revoked | 21 | 13 | Rights revoked; includes opposition/invalidation events in some records |
| Withdrawn – Voluntarily | 9 | 8 | Voluntary withdrawal |
Legal Status Breakdown: Key Reasons Behind Patent Lapses and Abandonments
The graphic highlights selected inactive categories rather than every legal-status category in the detailed table. Categories and percentages should not be treated as a complete mutually exclusive breakdown without reconciling the reporting scope and event taxonomy. In particular, withdrawal and rejection status labels do not establish non-response to office actions unless supported by prosecution histories.
Countries with The Highest Recorded Non-payment Counts
Maintenance-fee non-payment is most frequently recorded here in the United States (62) and India (44), followed by Germany (26), Spain (25) and Italy (22). These counts identify jurisdictions for follow-up, but do not indicate a higher country-level lapse probability without a denominator for maintained rights in each jurisdiction.
How Many Patents did Glenmark Pharmaceuticals File in Different Countries?
Countries in which Glenmark Pharmaceuticals Filed Patents
| Country | Patent |
| India | 412 |
| United States of America | 221 |
| Europe | 134 |
| Mexico | 94 |
| Japan | 91 |
| Brazil | 90 |
| China | 77 |
| Canada | 76 |
| South Africa | 67 |
| Australia | 65 |
| Malaysia | 56 |
| Israel | 54 |
| Singapore | 54 |
| Hong Kong | 49 |
| Eurasian | 48 |
| Austria | 42 |
| Philippines | 41 |
| Chile | 40 |
| Viet Nam | 39 |
| Korea (South) | 39 |
| Africa | 36 |
| New Zealand | 36 |
| Taiwan | 32 |
| Russia | 30 |
| Argentina | 30 |
| Germany | 29 |
| Spain | 28 |
| Peru | 27 |
| Italy | 25 |
| Thailand | 24 |
| Indonesia | 21 |
| Colombia | 18 |
| Denmark | 17 |
| Morocco | 15 |
| Poland | 15 |
| Slovenia | 13 |
| Hungary | 13 |
| Ukraine | 13 |
| Norway | 12 |
| Portugal | 11 |
| United Kingdom | 11 |
| Slovakia | 11 |
| Turkey | 9 |
| Tunisia | 9 |
| Malta | 9 |
| Georgia | 8 |
| Uzbekistan | 6 |
| Cyprus | 5 |
| Saudi Arabia | 5 |
| Switzerland | 4 |
| Kenya | 4 |
| Estonia | 3 |
| Croatia | 3 |
| Cuba | 2 |
| Algeria | 2 |
| Albania | 2 |
| Egypt | 2 |
| Lithuania | 1 |
| Serbia | 1 |
Track Every Patent Move in Real Time Across 70+ Jurisdictions with Elixir
Track Every Patent Move in Real Time Across 70+ Jurisdictions with Elixir
Where are Research Centres of Glenmark Pharmaceuticals Patents Located?
Glenmark Expands U.S. Dermatology Portfolio Through Product Differentiation
In October 2026, Glenmark introduced new 15 g and 45 g pump packs for Adapalene Gel 0.1% in the U.S., targeting an OTC market valued at approximately $45.8 million annually. The launch highlights Glenmark’s focus on improving product convenience and strengthening its dermatology portfolio through packaging differentiation, rather than introducing a new drug formulation. However, no new patent directly associated with these pump packs has been verified.
Glenmark Secures FDA Approval with 180-Day Exclusivity for Fluticasone Inhaler
In March 2026, Glenmark received U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol (44 mcg), becoming the first approved applicant under the Competitive Generic Therapy (CGT) pathway. The approval made Glenmark eligible for 180-day exclusivity following commercialization, targeting a U.S. reference-product market worth approximately $520.1 million annually.
The approval strengthens Glenmark’s respiratory portfolio and highlights its capabilities in complex generic inhalers, where formulation and drug-delivery requirements create technical barriers. Unlike patent protection, CGT exclusivity offers a temporary regulatory advantage, potentially allowing Glenmark to establish its market position before additional generic competitors enter.
10 Best Glenmark Pharmaceuticals Patents
WO2006040625A1 is the most popular patent in the Glenmark Pharmaceuticals portfolio. It has received 279 citations so far from companies like Companies, Boehringer Ingelheim International Gmbh, Phenomix Corporation and Arena Pharmaceuticals, Inc.
Below is the list of 10 most cited patents of Glenmark Pharmaceuticals:
| Publication Number | Citation Count |
| WO2006040625A1 | 279 |
| WO2015063339A1 | 211 |
| WO2013186692A1 | 192 |
| WO2012110860A1 | 179 |
| WO2013118071A1 | 153 |
| WO2015059618A1 | 137 |
| WO2013008171A1 | 125 |
| WO2013072825A1 | 116 |
| WO2014167444A1 | 111 |
| WO2010125469A1 | 110 |
What Percentage of Glenmark Pharmaceuticals US Patent Applications Were Granted?
Glenmark Pharmaceuticals (Excluding its subsidiaries) has filed 103 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 44 have been granted leading to a grant rate of 45.36 %.
Below are the key stats of Glenmark Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Glenmark Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Michael E Carmen Esq | 60 | 22.41% |
| Ryan Mason & Lewis Llp | 18 | 88.89% |
| Glenmark Pharmaceuticals (In House Counsel) | 19 | 83.34% |
| Davidson Kappel Llc | 2 | 50.00% |
| Dilworth & Barrese Llp | 2 | 0.00% |
| Hunton Andrews Kurth Llp Hak Ny | 1 | 0.00% |
| Lerner David Littenberg | 1 | 0% |
What are Glydways key innovation segments?
What Technologies are Covered by Glydways?
The chart below distributes patents filed by Glydways